Swiss Capital Markets Stock News

UBS Group AG recently outlined further Credit Suisse integration steps, including multi-wave job cuts through 2026 and leadership changes in operations and technology, with Group Technology set to report to incoming Group Chief Operating Officer Beatriz Martin from January 2026. By consolidating technology under the Group COO and emphasizing artificial intelligence and IT migration, UBS is signaling a push to streamline operations while completing the complex Credit Suisse integration. We’ll...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Huber+Suhner fair value estimate is CHF109 Current share price...

Key Insights The projected fair value for Amrize is CHF82.29 based on 2 Stage Free Cash Flow to Equity Current share...

Many investors define successful investing as beating the market average over the long term. But if you try your hand...

Jungfraubahn Holding's (VTX:JFN) stock is up by a considerable 29% over the past three months. Given that the market...

There wouldn't be many who think Compagnie Financière Tradition SA's ( VTX:CFT ) price-to-earnings (or "P/E") ratio of...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Dätwyler Holding AG ( VTX:DAE ) shareholders should be happy to see the share price up 12% in the last month. But if...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...

Novartis (SWX:NOVN) has been grinding higher, with shares up around 7 % over the past month and nearly 30 % over the past year, as investors lean into its steady earnings and pipeline story. See our latest analysis for Novartis. That move has been underpinned by solid execution rather than hype, with the roughly 30 % one year total shareholder return riding a clear uptrend in the share price as investors warm to its growth and defensiveness. If Novartis has you rethinking your healthcare...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...

Nestlé USA’s CEO Marty Thompson has recently intensified a review of the U.S. portfolio, using blind taste tests, product reformulations and packaging changes while weighing divestments and options for Blue Bottle coffee to better match shifting consumer preferences and spending. This sharper focus on core brands and willingness to shed underperformers hints at a leaner, more responsive U.S. business that could influence how investors view Nestlé’s broader growth ambitions and execution...

By buying an index fund, investors can approximate the average market return. But many of us dare to dream of bigger...

When close to half the companies operating in the Machinery industry in Switzerland have price-to-sales ratios (or...

If you are wondering whether Novartis is still attractively priced today, or if most of the upside has already gone to earlier investors, you are in the right place to unpack what the current market is really pricing in. Novartis has quietly been rewarding patient shareholders, with the stock up 1.7% over the last week, 5.6% over the past month, and 21.0% year to date, adding to a 28.2% gain over 1 year, 50.6% over 3 years, and 75.4% over 5 years. Those gains sit against a backdrop of...

UBS Group (SWX:UBSG) is back in focus after a shake up in its operations and technology leadership, just as Swiss lawmakers debate looser capital rules that could reshape the bank’s balance sheet and strategic flexibility. See our latest analysis for UBS Group. Those leadership changes and potential capital rule relief are landing against a strong backdrop, with UBS’s share price at about $36.7 after a 1 month share price return of 21.20 percent and a 5 year total shareholder return of 235.08...

Wondering if Roche Holding is still a smart buy after its strong run, or if the upside is already priced in? This breakdown is designed to give you a clear, valuation-driven view. The stock has climbed 0.5% over the last week, 4.2% over the past month, and is now up 24.5% year to date and 33.8% over the last year. This naturally raises the question of whether the current price fully reflects its prospects. Recent gains have come as investors refocus on Roche's late-stage pipeline, strategic...

In mid-December 2025, the Canadian Space Agency awarded ABB a contract to develop the concept for the Autonomous Lunar Exploration Infrared Spectrometer (ALExIS) for Canada’s Lunar Utility Rover, adapting its industrial Fourier Transform Infrared Spectrometer technology to analyze the Moon’s soil chemistry. This project highlights ABB’s space instrumentation expertise and extends its optical payload footprint from Earth-orbiting satellites to future lunar surface exploration, deepening its...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...

Forbo Holding AG ( VTX:FORN ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

It is hard to get excited after looking at Kardex Holding's (VTX:KARN) recent performance, when its stock has declined...